(VIANEWS) – The NASDAQ opens in less than five hours and NeuroMetrix‘s pre-market value is already 10% down.
The last session, NASDAQ ended with NeuroMetrix (NURO) dropping 1.96% to $3.00. NASDAQ fell 1.37% to $11,066.81, after three consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session.
NeuroMetrix, Inc. is a healthcare company that designs, builds, and markets medical devices to stimulate and analyze nerve responses for therapeutic and diagnostic purposes. It operates in North America, Europe, Japan, China, Japan, China, Mexico, China, Japan, China, China, Middle East, and Mexico. DPNCheck is a nerve conduction test used for diagnosing peripheral neuropathies such as diabetes peripheral neuropathy. Quell, a wearable device that provides symptomatic relief, and manages chronic pain, are its primary products. ADVANCE, a platform to perform nerve conduction studies, is the company’s main product. It sells its products to primary care doctors, occupational health, primary and internal medicine specialists, as well as primary care physicians. NeuroMetrix, Inc., was founded in 1996. It is located in Woburn, Massachusetts.
Today’s last reported volume for NeuroMetrix is 19558, 79.16% below its average volume of 93887.
NeuroMetrix’s last close was $3.00, 80.58% below its 52-week high of $15.45.
Year-on-year quarterly revenue growth declined by 3.4%, now sitting on 8.33M for the twelve trailing months.
NeuroMetrix’s Stock Yearly Top and Bottom Value
NeuroMetrix’s stock is valued at $3.00 at 05:21 EST, way under its 52-week high of $15.45 and way higher than its 52-week low of $2.70.
NeuroMetrix’s Moving Average
NeuroMetrix’s value is way below its 50-day moving average of $3.49 and way under its 200-day moving average of $4.13.
NeuroMetrix’s last day, last week, and last month’s current intraday variation average was 2.00%, 3.21%, and 2.67%, respectively.
NeuroMetrix’s highest amplitude of average volatility was 5.33% (day), 5.28% (last week), and 6.14% (last month), respectively.
More news about NeuroMetrix (NURO).